Medicenna Therapeutics Corp. announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicennas financial strategy to support the Companys growth.

This appointment underscores the Company's commitment to expanding its operations in Boston and follows the recent appointment of Mr. Brent Meadows as Chief Business Officer. Mr. Caravella brings to Medicenna over 20 years of global healthcare, financial and operational experience. Most recently, he served as CFO at Biotheryx, where he led the finance, investor relations and operationalfunctions and supported activities associated with an up to approximately $350 million collaboration with Incyte.

Prior to Biotheryx, he served as Vice President of Finance at Tango Therapeutics, where he built and led the finance and accounting functions, successfully supported approximately $110 million in private financings and an approximately $350 million SPAC and PIPE transaction. Previously, Jeff held senior finance roles at Editas Medicine, Charles River Laboratories and Johnson &Johnson. During his10-year tenure at Johnson &Johnson, he provided financial leadership on multiple licensing and option agreements with a potential cumulative value of over $1.4 billion and supported financial analysis, due diligence and integration of several acquisitions ranging in value from $100 million to $20 billion.

Mr. Caravella earned his B.S. and M.B.A. from Syracuse University.